JAMA | The Rational Clinical Examination

Did This Patient Have Cardiac Syncope? The Rational Clinical Examination Systematic Review

Omar T. Albassam, MD; Robert J. Redelmeier; Steven Shadowitz, MD, MSc; Aatif M. Husain, MD; David Simel, MD, MHS; Edward E. Etchells, MD, MSc

IMPORTANCE Syncope can result from a reduction in cardiac output from serious cardiac conditions, such as arrhythmias or structural heart disease (cardiac syncope), or other causes, such as vasovagal syncope or orthostatic hypotension.

OBJECTIVE To perform a systematic review of studies of the accuracy of the clinical examination for identifying patients with cardiac syncope.

STUDY SELECTION Studies of adults presenting to primary care, emergency departments, or referred to specialty clinics.

DATA EXTRACTION AND SYNTHESIS Relevant data were abstracted from articles in databases through April 9, 2019, and methodologic quality was assessed. Included studies had an independent comparison to a reference standard.

MAIN OUTCOMES AND MEASURES Sensitivity, specificity, and likelihood ratios (LRs).

RESULTS Eleven studies of cardiac syncope (N = 4317) were included. Age at first syncope of at least 35 years was associated with greater likelihood of cardiac syncope (n = 323; sensitivity, 91% [95% CI, 85%-97%]; specificity, 72% [95% CI, 66%-78%]; LR, 3.3 [95% CI, 2.6-4.1), while age younger than 35 years was associated with a lower likelihood (LR, 0.13 [95% CI, 0.06-0.25]). A history of atrial fibrillation or flutter (n = 323; sensitivity, 13% [95% CI, 6%-20%]; specificity, 98% [95% CI, 96%-100%]; LR, 7.3 [95% CI, 2.4-22]), or known severe structural heart disease (n = 222; range of sensitivity, 35%-51%, range of specificity, 84%-93%; range of LR, 3.3-4.8; 2 studies) were associated with greater likelihood of cardiac syncope. Symptoms prior to syncope that were associated with lower likelihood of cardiac syncope were mood change or prodromal preoccupation with details (n = 323; sensitivity, 2% [95% CI, 0%-5%]; specificity, 76% [95% CI, 71%-81%]; LR, 0.09 [95% CI, 0.02-0.38]), feeling cold (n = 412; sensitivity, 2% [95% CI, 0%-5%]; specificity, 89% [95% CI, 85%-93%]; LR, 0.16 [95% CI, 0.06-0.64]), or headache (n = 323; sensitivity, 3% [95% CI, 0%-7%]; specificity, 80% [95% CI, 75%-85%]; LR, 0.17 [95% CI, 0.06-0.55]). Cyanosis witnessed during the episode was associated with higher likelihood of cardiac syncope (n = 323; sensitivity, 8% [95% CI, 2%-14%]; specificity, 99% [95% CI, 98%-100%]; LR, 6.2 [95% CI, 1.6-24]). Mood changes after syncope (n = 323; sensitivity, 3% [95% CI, 0%-7%]; specificity, 83% [95% CI, 78%-88%]; LR, 0.21 [95% CI, 0.06-0.65]) and inability to remember behavior prior to syncope (n = 323; sensitivity, 5% [95% CI, 0%-9%]; specificity, 82% [95% CI, 77%-87%]; LR, 0.25, [95% CI, 0.09-0.69]) were associated with lower likelihood of cardiac syncope. Two studies prospectively validated the accuracy of the multivariable Evaluation of Guidelines in Syncope Study (EGSYS) score, which is based on 6 clinical variables. An EGSYS score of less than 3 was associated with lower likelihood of cardiac syncope (n = 456; range of sensitivity, 89%-91%, range of specificity, 69%-73%; range of LR, 0.12-0.17; 2 studies). Cardiac biomarkers show promising diagnostic accuracy for cardiac syncope, but diagnostic thresholds require validation.

CONCLUSIONS AND RELEVANCE The clinical examination, including the electrocardiogram as part of multivariable scores, can accurately identify patients with and without cardiac syncope.

JAMA. 2019;321(24):2448-2457. doi:10.1001/jama.2019.8001

Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Edward E. Etchells, MD, MSc, Division of General Internal Medicine, Sunnybrook Health Sciences Center, 2075 Bayview Ave, Room H469, Toronto, ON M4N 3M5, Canada (edward. etchells@sunnybrook.ca).

Clinical Scenario

A 70-year-old woman presented to the clinic with her son for urgent assessment of her transient loss of consciousness. There was no history of episodes of loss of consciousness or cardiac or neurologic disease. Prior to the episode, she was sitting at the table eating breakfast. She felt nauseated and warm but did not experience chest pain, shortness of breath, palpitations, head turning, déjà vu, or jamais vu prior to the episode. She lost consciousness and her son lowered her to the ground. He observed generalized asymmetric limb twitching for less than 10 seconds. He did not see his mother turn blue during the loss of consciousness, which lasted for approximately 60 seconds. After the episode, the patient remembered feeling cold just prior to the loss of consciousness. She was not confused after the loss of consciousness and had normal mental status within 5 minutes. Her son persuaded her to be evaluated at the clinic the day after the episode. On examination, her heart rate was 70/ min and regular and her blood pressure was 135/85 mm Hg in both arms while sitting and standing. There was no trauma to the tongue and the cardiac and neurologic examination findings were normal. A 12-lead electrocardiogram (ECG) showed normal sinus rhythm at 80/min, with normal PR interval, QRS duration and axis, and QT interval. Does this patient have cardiac syncope?

Why Is This an Important Question to Answer With the Clinical Examination?

Syncope is transient loss of consciousness with spontaneous recovery due to a global reduction in cerebral perfusion. Syncope may be due to serious or benign causes, so accurate diagnosis is essential. The most common causes of syncope are cardiac syncope, reflex syncope, and orthostatic hypotension. Transient loss of consciousness with spontaneous recovery can also be due to seizures and rare causes (**Box**). This review focuses on the accuracy of the clinical examination for detecting cardiac syncope. Risk assessments of patients with unexplained syncope in the emergency department, which predict heterogeneous clinical events rather than identifying a specific diagnosis, ³ are not addressed.

The Anatomic/Physiologic Origins of the Symptoms and Signs Used to Answer This Question

In cardiac syncope, the primary event is a marked reduction in cardiac output due to cardiopulmonary disease, such as arrhythmia, structural heart disease, or pulmonary embolism that leads to cerebral hypoperfusion. The event may occur at rest, in the supine position, or during effort when the patient is unable to increase the cardiac output to meet the increased demand. Cardiac syncope may be preceded by chest pain, shortness of breath, or palpitations. Patients may have witnessed cyanosis during unconsciousness. After awakening, patients may have persistent cardiac symptoms, abnormalities in heart rate or rhythm, abnormal cardiac physical examination findings, an abnormal electrocardiogram, or abnormal serum troponin or B-type natriuretic peptide levels.

Box. Causes of Nontraumatic Transient Loss of Consciousness With Spontaneous Recovery^a

| with Spontaneous Recovery |
|---|
| Syncope Cardiac |
| Orthostatic hypotension |
| Reflex Vasovagal |
| Situational |
| Carotid sinus hypersensitivity |
| Seizure Generalized onset Motor |
| Nonmotor |
| Focal onset with impaired awareness ^b Motor |
| Nonmotor |
| Rare Causes |
| Subclavian steal syndrome |
| Vertebrobasilar transient ischemic attack |
| Subarachnoid hemorrhage |

^a Adapted from Fisher et al¹ and Brignole et al.²

^b Focal seizures may also progress to bilateral tonic-clonic seizures with impaired awareness.


Reflex syncope refers to a centrally mediated reflex reduction in heart rate, systemic vascular resistance, or both. Vasovagal syncope, the most common form of reflex syncope, is usually initiated by prolonged sitting or standing, which results in 500 to 800 mL of blood remaining in the distensible veins below the heart. Venous return, cardiac output, and blood pressure decrease during reflex syncope. These changes are detected by intracardiac and arterial baroreceptors, signaling the central nervous system to preserve cerebral perfusion through reduced vagal tone and increased sympathetic tone. In some patients, the reduction in vagal tone and increase in sympathetic tone are exaggerated, leading to excessive increases in heart rate and myocardial contractility against a relatively underfilled ventricle. Intracardiac baroreceptors become paradoxically overstimulated, leading to a second centrally mediated reflex characterized by an increased vagal tone and reduced sympathetic tone, reduced heart rate, reduced peripheral vascular resistance, and a global reduction in cerebral perfusion. Reflex syncope may also be precipitated by afferent central stimuli, such as pain or the sight of blood during venipuncture; afferent visceral stimuli, such as a distended stomach or bladder; or pressure on the carotid sinus baroreceptor, such as from a tight collared shirt while turning the neck. The efferent vagal component of the reflex leads to autonomic symptoms, such as headache, sweating, a sense of cold or warmth, nausea, vomiting, abdominal discomfort, or urge to defecate (Figure 1).

In syncope due to orthostatic hypotension, the primary disorder may be a reduction in venous return, due to conditions such as volume depletion or gastrointestinal bleeding or a reduction in systemic vascular resistance, caused by medications or disorders of

Figure 1. Stages of Reflex Syncope

1 Initiation of reflex syncope

- Venous blood pooling from prolonged sitting or standing
- Central stimuli (eg, pain, sight of blood, emotional stress)
- Visceral stimuli (eg, distended stomach or bladder)
- Carotid sinus baroreceptor stimulation (eg, pressure on the neck)
- Intracardiac baroreceptor stimulation



the autonomic nervous system. Patients with orthostatic hypotension typically experience syncope within 5 minutes of sitting or standing. The patient may experience a warning of blurred vision or lightheadedness prior to loss of consciousness.

Transient loss of consciousness with spontaneous recovery may be due to seizures. Seizures are a constellation of symptoms that occur because of a transient episode of abnormal excessive or synchronous neuronal activity in the brain.¹ There are 2 main types of seizure onset, focal and generalized. In focal seizures, awareness may be preserved or lost. Focal seizures also may be associated with a variety of motor or nonmotor components. Motor features of focal seizures include automatisms or tonic, clonic, or hyperkinetic activity. Behavioral arrest and cognitive, autonomic, or emotional changes are nonmotor signs of focal seizures. Generalized seizures can also present with motor and nonmotor features. The motor features include tonic-clonic, myoclonic, or other types of motor activity. Nonmotor features of generalized seizures include staring spells, drop attacks, and eyelid myoclonus.¹ During the seizure, the patient may appear cyanotic because they are not breathing. The patient's relaxed tongue may be injured by the posterior teeth during tonic contraction of the jaw. Although patients with syncope or seizure may not recall symptoms just prior to the loss of consciousness, patients with syncope usually rapidly regain awareness in their environment, while patients with seizure may have prolonged confusion (ie, postictal confusion).

Witness accounts of the loss of consciousness are extremely valuable. Witnesses might report brief asymmetric or symmetric myoclonic or tonic-clonic movements at the time of loss of consciousness in patients with syncope. These movements should not be mistaken for a seizure.⁴⁻⁶ The movements typically occur at the time of or within 10 seconds after the loss of consciousness, but not before. The duration of movements is usually less than 15 seconds. When eliciting the history of abnormal movements from a witness, the clinician may avoid diagnostic confusion with seizures by giving a timed physical demonstration of sustained tonic-clonic activity indicative of seizures. First responder reports can also provide important information, including vital signs, cardiac rhythm, and neurologic status shortly after the episode.

Prevalence

The incidence of syncope in adults is approximately 0.6% per year, increasing to 2% to 6% in elderly patients, and the prevalence of syncope in adults is 18% to 47%.^{7.8} The cause of transient loss of consciousness for patients presenting to primary care or the emergency department is cardiac syncope in 5% to 21% of cases, vasovagal syncope in 21% to 48%, orthostatic hypotension in 4% to 24%, nonsyncopal syndromes (such as psychogenic nonepileptiform events or cataplexy) in 8% to 20%, and unexplained syncope in 17% to 37%.² Syncope is more common than seizures. The incidence of seizures is about 0.05% per year and the prevalence of seizures is about 0.3% to 1.7%.⁹

Methods

Search Strategy and Study Selection

The MEDLINE, Embase, CINAHL, and Cochrane databases were searched for articles published from the earliest possible date to April 9, 2019, using the following Medical Subject Heading terms and search strategy: "Physical examination or medical history taking or professional competence or sensitivity and specificity or reproducibility of results or observer variation or decision support techniques or Bayes theorem" and "syncope or consciousness or unconsciousness or seizures." The terms "consciousness," "unconsciousness," and "seizures" were added to identify potentially relevant articles that were not indexed with the term syncope. The Medical Subject Heading terms were replaced with the appropriate Emtree terms when Embase was searched, along with searching for key words related to each Medical Subject Heading term in the title and abstract. The searches were limited to articles published in English.

Pairs of investigators (O.T.A., R.J.R., S.S., or E.E.E.) independently reviewed all abstracts for English-language studies that included at least 10 human participants aged 12 years or older. An age of 12 years or older was included at this stage of review because studies can included a broad range of ages that span from adolescence to adulthood.

Studies with a valid reference standard, ¹⁰ such as cardiology consultation; noninvasive cardiac evaluation, such as echocardiography, Holter monitoring, loop monitoring, tilt table testing, or carotid sinus massage; or invasive cardiac evaluation, such as cardiac catheterization or electrophysiologic study, were included. Studies restricted to patients with recurrent unexplained syncope, a single defined cause of syncope, or who had completed invasive cardiac evaluation were excluded. The full text article of any abstract that was considered potentially relevant by either investigator was obtained. Pairs of investigators (O.T.A., R.J.R., S.S., or E.E.E.) independently reapplied the inclusion criteria to the full text articles. Additional articles were identified by searching the bibliographies of retrieved articles and position papers of professional organizations.

Assessment of Methodologic Quality and Data Abstraction

Two important methodologic issues could bias estimates of the accuracy of the clinical examination for detecting cardiac syncope. First, clinical findings alone are an accepted reference standard for

| Finding | No. of Patients (No. With Cardiac Syncope) | Sensitivity (95% CI) | Specificity (95% CI) | LR+ (95% CI)ª | LR- (95% CI) ^a |
|---|--|--------------------------|---|--|---------------------------------|
| Patient Demographics | | | | . , | . , |
| Atrial fibrillation or flutter ¹⁷ | 323 (88) | 0.13 (0.06-0.20) | 0.98 (0.96-1.0) | 7.3 (2.4-22) | 0.89 (0.82-0.97) |
| Severe structural heart disease ^{18,19b} | 222 (98) | 0.35-0.51 | 0.84-0.93 | 3.3-4.8 | 0.58-0.70 |
| listory of heart failure ^{18,27b} | 1633 (299) | 0.16-0.41 | 0.88-0.94 | 2.7-3.4 | 0.39-0.78 |
| Age at first syncopal spell >35 y ¹⁷ | 323 (88) | 0.91 (0.85-0.97) | 0.72 (0.66-0.78) | 3.3 (2.6-4.1) | 0.13 (0.06-0.25 |
| Precipitating or Predisposing Factors | | | | | |
| During effort ^{18,21b} | 421 (122) | 0.12-0.14 | 0.92-0.99 | 1.4-15 | 0.88-0.96 |
| While supine ^{18,21b} | 421 (122) | 0.06-0.14 | 0.94-0.97 | 1.1-4.9 | 0.89-1.0 |
| Prolonged sitting/standing ¹⁷ | 323 (88) | 0.38 (0.28-0.48) | 0.31 (0.25-0.37) | 0.54 (0.41-0.72) | 2.0 (1.6-2.6) |
| On way to the toilet ¹⁷ | 323 (88) | 0.05 (0-0.09) | 0.84 (0.79-0.89) | 0.28 (0.10-0.76) | 1.1 (1.1-1.2) |
| Stress ¹⁷ | 323 (88) | 0.08 (0.02-0.14) | 0.68 (0.62-0.74) | 0.25 (0.12-0.51) | 1.4 (1.2-1.5) |
| Varm place ¹⁷ | 323 (88) | 0.09 (0.03-0.15) | 0.45 (0.39-0.51) | 0.17 (0.08-0.33) | 2.0 (1.7-2.4) |
| Pain or medical procedure ¹⁷ | 323 (88) | 0.06 (0.01-0.11) | 0.52 (0.46-0.58) | 0.12 (0.05-0.28) | 1.8 (1.5-2.1) |
| After using the toilet ¹⁷ | 323 (88) | 0 (0-0.03) | 0.89 (0.85-0.93) | 0.05 (0.003-0.85) | 1.1 (1.1-1.2) |
| Symptoms Prior to the Episode | | | | | |
| Dyspnea ^{18,19,21,23} | 699 (176) | 0.18 (0.08-0.36) | 0.95 (0.80-0.99) | 3.5 (1.5-9.1) | 0.87 (0.74-0.94) |
| Chest pain/angina ^{23,27b} | 1680 (255) | 0.06-0.19 | 0.95-0.98 | 3.4-3.8 | 0.71-0.79 |
| Palpitations ^{17,18,21-23,27} | 2836 (581) | 0.13 (0.09-0.19) | 0.93 (0.82-0.98) | 1.9 (0.86-4.5) | 0.94 (0.89-1.0) |
| Absence of prodromes ^{18,20-22} | 1031 (353) | 0.43 (0.35-0.51) | 0.73 (0.55-0.86) | 1.6 (1.0-2.6) | 0.79 (0.69-0.96 |
| Pallor ^{17,23,27} | 2003(343) | 0.22 (0.08-0.48) | 0.69 (0.34-0.90) | 0.69 (0.58-0.82) | 1.2 (1.0-1.4) |
| Blurred vision ^{17,20-23} | 1401 (397) | 0.16 (0.09-0.28) | 0.71 (0.56-0.83) | 0.55 (0.27-1.1) | 1.2 (0.96-1.5) |
| Diaphoresis ^{21-23,27} | 2352 (415) | 0.15 (0.10-0.23) | 0.69 (0.66-0.71) | 0.49 (0.33-0.71) | 1.2 (1.1-1.3) |
| Vausea ^{17,18,21-23,27} | 2836 (581) | 0.11 (0.07-0.18) | 0.74 (0.65-0.81) | 0.44 (0.31-0.62) | 1.1 (1.1-1.3) |
| Awareness of being about to faint ^{22,23b} | 620 (150) | 0.12-0.38 | 0.64-0.66 | 0.35-1.0 | 0.97-1.3 |
| Sweating or warm feeling ¹⁷ | 323 (88) | 0.24 (0.15-0.33) | 0.38 (0.32-0.44) | 0.38 (0.26-0.57) | 2.0 (1.6-2.5) |
| Auditory distortion ¹⁷ | 323 (88) | 0.14 (0.07-0.21) | 0.64 (0.58-0.7) | 0.38 (0.22-0.66) | 1.3 (1.2-1.5) |
| ightheadedness ²² | 412 (116) | 0.08 (0.03-0.13) | 0.8 (0.75-0.85) | 0.38 (0.20-0.75) | 1.2 (1.1-1.2) |
| Numbness or tingling ¹⁷ | 323 (88) | 0.09 (0.03-0.15) | 0.72 (0.66-0.78) | 0.33 (0.16-0.66) | 1.3 (1.1-1.4) |
| Abdominal discomfort ^{17,23b} | 531 (122) | 0.029 -0.034 | 0.84-0.93 | 0.21-0.39 | 1.0-1.2 |
| Headache ¹⁷ | 323 (88) | 0.03 (0-0.07) | 0.8 (0.75-0.85) | 0.17 (0.06-0.55) | 1.2 (1.1-1.3) |
| Feeling cold ²² | 412 (116) | 0.02 (0-0.05) | 0.89 (0.85-0.93) | 0.16 (0.04-0.64) | 1.1 (1.0-1.2) |
| Mood changes or prodromal | 323 (88) | 0.02 (0-0.05) | 0.76 (0.71-0.81) | 0.09 (0.02-0.38) | 1.3 (1.2-1.4) |
| preoccupation with details ¹⁷ | | | | | |
| During and After the Episode | | | | | |
| Cyanotic during syncope ¹⁷ | 323 (88) | 0.08 (0.02-0.14) | 0.99 (0.98-1.0) | 6.2 (1.6-24) | 0.93 (0.88-0.99) |
| njury ^{19,27b} | 1533 (241) | 0.16-0.25 | 0.80-0.86 | 1.13-1.28 | 0.90-0.98 |
| lumbness or tingling ¹⁷ | 323 (88) | 0.06 (0.01-0.11) | 0.82 (0.77-0.87) | 0.31 (0.13-0.76) | 1.2 (1.1-1.2) |
| Vausea ^{17,22b} | 735 (204) | 0.06-0.10 | 0.65-0.84 | 0.29-0.38 | 1.1-1.4 |
| Cannot remember behavior during syncope ¹⁷ | 323 (88) | 0.05 (0-0.09) | 0.82 (0.77-0.87) | 0.25 (0.09-0.69) | 1.2 (1.1-1.2) |
| Nood changes ¹⁷ | 323 (88) | 0.03 (0-0.07) | 0.83 (0.78-0.88) | 0.21 (0.06-0.65) | 1.2 (1.1-1.2) |
| Combinations of Findings | | | | | |
| leart disease, abnormal ECG, or both ²⁰ | 198 (115) | 0.88 (0.82-0.94) | 0.61 (0.51-0.71) | 2.3 (1.7-3.0) | 0.20 (0.12-0.33) |
| GSYS score $\geq 3^{20,21b}$ | 456 (150) | 0.89-0.91 | 0.69-0.73 | 2.8-3.3 | 0.12-0.17 |
| /asovagal score<-2 ^{17,25b} | 703 (116) | 0.32-0.91 | 0.81-0.89 | 1.7-8.6 | 0.10-0.84 |
| obreviations: ECG, electrocardiogram; EG mcope Study; LR, likelihood ratio. When a finding is present, as the LR+ becc he likelihood of cardiac syncope increase | omes increasingly grea | decr ter than 1, grea | becomes increasingly les reases. When a finding is p iter than 1, the likelihood o sitivity, specificity, and LR | present and the LR– been of noncardiac syncope i | comes increasingly ncreases. |

vasovagal syncope,² orthostatic hypotension, and seizures. Clinical findings that define the reference standard will have high estimates of specificity. Second, the reference standard evaluation of syncope

is guided by results of the clinical examination. Patients with a typical history for vasovagal syncope, normal cardiac examination findings, and a normal electrocardiogram, will generally not undergo further

| Table 2. The Evaluation of Guidelines in Syncope Study (EGSYS) Scores ^a |
|--|
|--|

| Clinical Variable | Points |
|---|--------|
| Palpitations | 4 |
| Abnormal ECG/heart disease ^{c,d} | 3 |
| Effort syncope | 3 |
| Syncope in supine position | 2 |
| Neurovegetative prodromes ^e | -1 |
| Precipitating and predisposive factors ^f | -1 |

Abbreviation: ECG, electrocardiogram

^a Adapted from Kariman et al²⁰ and Del Rosso et al.²¹

^b A total score of 3 or more implies an increased risk of cardiac syncope.

- ^c Abnormal ECG was defined as any of the following: bradycardia less than 40/min, repetitive sinoatrial blocks, sinus pauses greater than 3 seconds, ST changes >1 mm elevation or depression, QT prolongation ≥440 ms or more, ventricular tachycardia, atrioventricular block (mobitz 2, second or third degree atrioventricular block, alternating left and right bundle branch block, sick sinus syndrome, ventricular and rapid paroxysmal supraventricular arrhythmias, or sinus pauses and pacemaker malfunction.
- ^d Heart disease was defined as congestive heart failure or any form of structural heart disease, including ischemic disease, valvular dysfunction, cardiomyopathy, and congenital heart disease.
- ^e Neurovegetative prodromes: nausea, vomiting, abdominal discomfort, feeling of cold, sweating, aura, pain in neck or shoulders, blurred vision, and dizziness.
- ^f Precipitating and predisposive factors: position (supine, sitting or standing); activity (rest, change in posture, during or after exercise, during or immediately after urination, defaecation, cough or swallowing); predisposing factors (eg, crowded or warm places, prolonged standing, postprandial period); and precipitating events (eg, fear, intense pain, neck movements).

testing. This raises the potential for misclassification bias, ¹¹ which could lead to overestimates of sensitivity and specificity.

Pairs of investigators (O.T.A., R.J.R., S.S., or E.E.E.) independently completed qualitative methodological reviews using the Quality Assessment of Diagnostic Accuracy Studies tool¹² and resolved any disagreements by consensus. A third investigator (S.S. or E.E.E.) independently performed a qualitative methodologic review when consensus could not be reached. The level of evidence was assigned by adapting the grading system developed for the Rational Clinical Examination series.¹³ Level 1 studies were prospective studies of at least 100 consecutive patients who underwent an independent comparison to a reference standard evaluation. Level 2 studies were similar to level 1 studies but with fewer than 100 patients. Level 3 studies were comparisons of patients to a reference standard that otherwise did not meet criteria for level 1 or 2 studies, such as retrospective studies, studies of nonconsecutive patients, or studies in which the independence between the test and reference standard could be inferred, but not confirmed, from the study methods. Studies below level 3 evidence were excluded. Pairs of investigators (O.T.A., R.J.R., S.S., or E.E.E.) independently abstracted data and resolved any disagreements about abstracted data through discussion. A third investigator (S.S., E.E.E., or D.S.) independently abstracted data when an agreement could not be reached. Authors of published studies were contacted for methodologic information or additional data when necessary.

Analysis

The sensitivity and specificity CIs were estimated using exact methods if cells had zero values.¹⁴ If there were values of zero in the 2×2 matrix, 0.5 was added to each cell to calculate likelihood ratios. Findings evaluated in only 2 studies were summarized with the range. Findings evaluated in 3 studies were summarized with univariate random effects measures because bivariate methods may not work with few studies or small cell values.¹⁵ Findings evaluated in at least 4 studies were analyzed using bivariate random effects measures, which accounts for the heterogeneity between studies.¹⁶ We did not weigh for quality measures.

Results

After screening 11 460 abstracts and reviewing 552 full-text articles, 540 full-text articles were excluded because the study did not meet inclusion criteria after full-text review (n = 448), was below level 3 evidence (n = 75), did not evaluate any elements of the clinical examination (n = 13), or was a duplicate publication (n = 4) (eFigure in the Supplement). Of the remaining 12 studies, 11 addressed the question of cardiac syncope or other causes of syncope and 1 addressed the question of seizure or syncope.

Did This Patient Have Cardiac Syncope?

Among 11 studies that included 4317 total patients, ¹⁷⁻²⁷ 6 studies enrolled patients with syncope presenting to emergency departments, 3 enrolled patients admitted to hospitals for evaluation of syncope, and 2 enrolled inpatients and outpatients referred for evaluation of syncope. In most studies, the clinical examination was completed by study personnel or trained expert physicians. In these studies, 9% to 58% of patients had a final diagnosis of cardiac syncope and 3% to 37% remained undiagnosed after extensive workup. Four studies were graded as level 1, 2 were graded level 2, and the remaining 5 were graded level 3. Nine studies were prospective, all of which enrolled consecutive participants. Seven studies explicitly described independence between the index clinical examination and the reference standard assessment. Most studies did not explicitly ensure that the index clinical examination was independent of the reference standard assessment (Table 1 and Table 2; eTables 1-3 in the Supplement).

Patient Demographics

Age at first syncope of 35 years or older was associated with greater likelihood of cardiac syncope (n = 323; sensitivity, 91% [95% CI, 85%-97%]; specificity, 72% [95% CI, 66%-78%]; likelihood ratio [LR], 3.3 [95% CI, 2.6-4.1]), while age 35 years or younger was associated with lower likelihood of cardiac syncope (LR, 0.13 [95% CI, 0.06-0.25]). A history of atrial fibrillation or flutter (n = 323; sensitivity, 13% [95% CI, 6%-20%]; specificity, 98% [95% CI, 96%-100%]; LR, 7.3 [95% CI, 2.4-22]), heart failure (n = 1633; range of sensitivity, 16%-41%; range of specificity, 88%-94%; range of LR, 2.7-3.4; 2 studies), or known severe structural heart disease (n = 222; range of sensitivity, 35%-51%; range of specificity, 84%-93%; range of LR, 3.3-4.8; 2 studies) were associated with greater likelihood of cardiac syncope (Table 1; eTable 4 in the Supplement).

Precipitating and Predisposing Factors

Predisposing and precipitating factors that were associated with lower likelihood of cardiac syncope were pain or medical procedure prior to syncope (n = 323; sensitivity, 6% [95% CI, 1%-11%]; specificity, 52% [95% CI, 46%-58%]; LR, 0.12 [95% CI, 0.05-0.28])

Table 3. Cardiac Biomarkers of Patients in Studies Included in a Review of the Accuracy of Clinical Examinations for Detecting Cardiac Syncope

| | No. With Cardiac | | | | |
|--|------------------|----------------------|----------------------|---------------------|------------------|
| Finding | Syncope | Sensitivity (95% CI) | Specificity (95% CI) | LR+ (95% CI) | LR- (95% CI) |
| High-sensitivity cardiac troponin T >14 ng/L ²⁴ | 360 (80) | 0.74 (0.64-0.84) | 0.68 (0.63-0.73) | 2.3 (1.9-2.9) | 0.39 (0.26-0.56) |
| High-sensitivity cardiac troponin T ²⁷ | 1338 (221) | NA ^b | NA ^b | | NA ^b |
| >42 pg/mL | | | | 5.1 (3.6-7.1) | |
| 5-42 pg/mL | | | | 1.0 (0.91-1.1) | |
| <5 pg/mL | | | | 0.15 (0.08-0.31) | |
| High-sensitivity cardiac troponin I ²⁷ | 1338 (221) | NA ^b | NA ^b | | NA ^b |
| >31.3 pg/mL | | | | 5.4 (3.9-7.6) | |
| 2.2-31.3 pg/mL | | | | 0.96 (0.87-1.1) | |
| <2.2 pg/mL | | | | 0.18 (0.10-0.35) | |
| NT-proBNP above upper limit normal ^{18,19a} | 222 (98) | 0.90-0.90 | 0.49-0.52 | 1.8-1.9 | 0.20-0.21 |
| NT-proBNP ≥210.5 pg/ml ²⁶ | 100 (50) | 0.94 (0.9 -1.0) | 0.98 (0.94-1.0) | 47 (6.7-328) | 0.06 (0.02-0.18) |
| NT-proBNP ²⁷ | 1338 (221) | NA ^b | NA ^b | | NA ^b |
| >1966 pg/mL | | | | 5.8 (4.2-8.1) | |
| 69-1966 pg/mL | | | | 1.1 (1.0-1.2) | |
| <69 pg/mL | | | | 0.16 (0.09-0.28) | |
| BNP ²⁷ | 1338 (221) | NA ^b | NA ^b | | NA ^b |
| >302 pg/mL | | | | 6.3 (4.6-8.8) | |
| 15-302 pg/mL | | | | 0.91 (0.82-1.0) | |
| <15 pg/mL | | | | 0.20 (0.11-0.40) | |

Abbreviations: BNP, B-type natriuretic peptide; LR, likelihood ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NA, not applicable.

^b For ordinal results with 3 or more levels, sensitivity and specificity no longer apply. The serial LRs are shown for each threshold.

and LKS are reported as range

or syncope in a warm place (n = 323; sensitivity, 9% [95% CI, 3%-15%]; specificity, 45% [95% CI, 39%-51%]; LR, 0.17 [95% CI, 0.08-0.33]). Syncope after using the toilet was associated with a lower likelihood of cardiac syncope, but the CIs were wide (LR, 0.05 [95% CI, 0.003-0.85]). There were inconsistent results for syncope during effort and syncope while supine (Table 1; eTable 5 in the Supplement).

Symptoms Prior to Syncope

Dyspnea prior to syncope (n = 699; sensitivity, 18% [95% CI, 8%-36%]; specificity, 95% [95% CI, 80%-99%]; LR, 3.5 [95% CI, 1.5-9.1]) and chest pain prior to syncope (n = 1680; range of sensitivity, 6%-19%; range of specificity, 95%-98%; range of LR, 3.4-3.8; 2 studies) were associated with higher likelihood of cardiac syncope. There were inconsistent results for palpitations prior to syncope. Symptoms prior to syncope that were associated with lower likelihood of cardiac syncope were mood change or prodromal preoccupation with details (n = 323; sensitivity, 2% [95% CI, 0%-5%]; specificity, 76% [95% CI, 71%-81%]; LR, 0.09 [95% CI, 0.02-0.38]), feeling cold (n = 412; sensitivity, 2% [95% CI, 0%-5%]; specificity, 89% [95% CI, 85%-93%]; LR, 0.16 [95% CI, 0.06-0.64]), headache (n = 323; sensitivity, 3% [95% CI, 0%-7%]; specificity, 80% [95% CI, 75%-85%], LR, 0.17 [95% CI, 0.06-0.55]), or abdominal discomfort (n = 531; range of sensitivity, 2.9%-3.4%; range of specificity, 84%-93%; range of LR, 0.21-0.39; 2 studies). Pallor and absent prodrome were not associated with higher or lower likelihood of cardiac syncope (Table 1; eTable 6 in the Supplement).

Symptoms and Signs During and After Syncope

Cyanosis witnessed during the episode was associated with higher likelihood of cardiac syncope (n = 323; sensitivity, 8% [95% CI, 2%-14%]; specificity, 99% [95% CI, 98%-100%]; LR, 6.2 [95% CI, 1.6-24]). Mood changes after syncope (n = 323; sensitivity, 3% [95% CI, 0%-7%]; specificity, 83% [95% CI, 78%-88%]; LR, 0.21 [95% CI, 0.06-0.65]) and inability to remember behavior prior to syncope (n = 323; sensitivity, 5% [95% CI, 0%-9%]; specificity, 82% [95% CI, 77%-87%]; LR, 0.25 [95% CI, 0.09-0.69]) were associated with lower likelihood of cardiac syncope (Table 1; eTables 7 and 8 in the Supplement). Injury after syncope was not associated with higher or lower likelihood of cardiac syncope.

Combinations of Findings

Cardiac syncope was less likely if there was no history of heart disease and a normal ECG (n = 198; sensitivity, 88% [95% CI, 82%-94%]; specificity, 61% [95% CI, 51%-71%]; LR, 0.20 [95% CI, 0.12-0.33]). Two studies prospectively validated the accuracy of the multivariable Evaluation of Guidelines in Syncope Study (EGSYS) score (range, -2 to 12; higher scores indicate higher likelihood of cardiac syncope), which is based on 6 clinical variables (Table 1 and Table 2; eTable 9 in the Supplement) An EGSYS score less than 3 was associated with lower likelihood of cardiac syncope (n = 456; range of sensitivity, 89%-91%; range of specificity, 69%-73%; range of LR, 0.12-0.17; 2 studies).

One level 3 study (n = 323) retrospectively validated the multivariable vasovagal score (Table 1). The vasovagal score assigns

^a Upper limit of normal >156 pg/mL¹⁸ and ≥164 pg/mL¹⁹ Sensitivity, specificity, and LRs are reported as ranges.

| | LR (95% CI) | | | |
|---|------------------------|------------------|-----------------------|------------------|
| | When Finding Is Preser | ıt | When Finding Is Absen | t |
| Finding | Seizure | Syncope | Seizure | Syncope |
| Symptoms ²⁸ | | | | |
| Head turning | 14 (8.2-23) | 0.07 (0.04-0.12) | 0.59 (0.50-0.70) | 1.7 (1.4-2.0) |
| Jnusual posturing | 13 (7.6-24) | 0.08 (0.04-0.13) | 0.67 (0.58-0.77) | 1.5 (1.3-1.7) |
| Bedwetting | 6.7 (3.8-12) | 0.15 (0.08-0.26) | 0.79 (0.71-0.88) | 1.3 (1.1-1.4) |
| Blue color observed by bystanders | 5.8 (3.7-8.9) | 0.17 (0.11-0.27) | 0.72 (0.63-0.82) | 1.4 (1.2-1.6) |
| Limb jerking noted by others | 5.6 (4.3-7.2) | 0.18 (0.14-0.23) | 0.36 (0.27-0.48) | 2.8 (2.1-3.7) |
| Prodromal trembling | 4.9 (3.2-7.7) | 0.2 (0.13-0.31) | 0.75 (0.66-0.85) | 1.3 (1.2-1.5) |
| Prodromal preoccupation | 4.5 (1.8-11) | 0.22 (0.09-0.56) | 0.94 (0.89-0.99) | 1.1 (1.0-1.1) |
| Prodromal hallucinations | 4.5 (1.8-11) | 0.22 (0.09-0.56) | 0.94 (0.89-0.99) | 1.1 (1.0-1.1) |
| Any presyncope | 0.27 (0.19-0.39) | 3.7 (2.6-5.3) | 5.6 (4.4-7) | 0.18 (0.14-0.23) |
| Warmth before a spell | 0.23 (0.12-0.46) | 4.3 (2.2-8.3) | 1.4 (1.3-1.5) | 0.71 (0.67-0.77) |
| Any chest pain | 0.22 (0.12-0.39) | 4.5 (2.6-8.3) | 1.7 (1.5-1.8) | 0.59 (0.56-0.67) |
| Nausea before a spell | 0.21 (0.1-0.47) | 4.8 (2.1-10) | 1.3 (1.2-1.4) | 0.77 (0.71-0.83) |
| Remembered loss of consciousness | 0.21 (0.12-0.35) | 4.8 (2.9-8.3) | 2.1 (1.8-2.3) | 0.48 (0.43-0.56) |
| Presyncope with prolonged sitting/standing | 0.18 (0.08-0.4) | 5.6 (2.5-13) | 1.4 (1.3-1.5) | 0.71 (0.67-0.77) |
| Diaphoresis before a spell | 0.17 (0.08-0.37) | 5.9 (2.7-13) | 1.4 (1.3-1.6) | 0.71 (0.63-0.77) |
| Chest pain before a spell | 0.15 (0.04-0.61) | 6.7 (1.6-25) | 1.1 (1.1-1.2) | 0.91 (0.83-0.91) |
| Palpitations before loss of consciousness | 0.12 (0.04-0.31) | 8.3 (3.2-25) | 1.5 (1.4-1.6) | 0.67 (0.63-0.71) |
| Dyspnea before loss of consciousness | 0.08 (0.02-0.33) | 13 (3.0-50) | 1.3 (1.2-1.4) | 0.77 (0.71-0.83) |
| Loss of consciousness with prolonged sitting/standing | 0.05 (0.01-0.19) | 20 (5.3-100) | 1.6 (1.5-1.7) | 0.63 (0.59-0.67) |
| Coronary heart disease | 0.08 (0.02-0.31) | 13 (3.2-50) | 1.3 (1.2-1.4) | 0.77 (0.71-0.83) |
| Signs ²⁸ | | | | |
| Cut tongue | 17 (9.9-29) | 0.06 (0.03-0.10) | 0.56 (0.47-0.67) | 1.8 (1.5-2.1) |
| Behaviors not recalled | 4 (3-5.3) | 0.25 (0.19-0.33) | 0.54 (0.44-0.67) | 1.8 (1.5-2.3) |

Abbreviation: LR, likelihood ratio.

^a Adapted from Sheldon et al.²⁸

points to 7 clinical variables (score range, -14 to 6; a lower score indicates a higher likelihood of cardiac syncope): (1) history of bifascicular block, asystole, supraventricular tachycardia, and/or diabetes (-5 points); (2) blue in the face, as noted by bystanders (-4 points); (3) 35 years of age or older (-3 points); (4) memory of being unconscious (-2 points); (5) lightheaded spells or fainting with prolonged sitting or standing (+1 point); (6) sweating or feeling warm before fainting (+2 points); and (7) lightheaded spells or fainting with pain or in medical settings (+3 points). A vasovagal score less than -2 was associated with a lower likelihood of cardiac syncope (sensitivity, 91% [95% CI, 85%-97%]; specificity, 89% [95% CI, 85%-93%]; LR for a vasovagal score <-2, 8.6 [95% CI, 5.9-13]), whereas cardiac syncope was unlikely with a vasovagal score of at least -2 (LR for a vasovagal score ≥-2, 0.10 [95% CI, 0.05-0.20]). A subsequent level 3 study²⁵ of patients with vasovagal syncope and cardiac syncope found that a vasovagal score of less than -2 was associated with a slightly higher likelihood of cardiac syncope (n = 265; sensitivity, 32% [95% CI, 15%-49%]; specificity, 81% [95% CI, 77%-85%]; LR for a vasovagal score <-2, 1.7 [95% CI, 0.95-3.0]), whereas a vasovagal score of at least -2 was not associated with a difference in the likelihood of cardiac syncope (LR for a vasovagal score ≥ -2 , 0.84 [95% CI, 0.65-1.1]).

Biomarkers

A high-sensitivity cardiac troponin T (Roche assay) greater than or equal to 42 ng/L was required to achieve a predefined specificity of 95% for cardiac syncope (LR, 5.1 [95% CI, 3.6-7.1]), whereas a threshold of greater than or equal to 31.3 ng/L was required for the highsensitivity cardiac troponin I (Abbott assay) to achieve a specificity of 95% (LR, 5.4 [95% CI, 3.9-7.6]).²⁷ A predefined sensitivity of 95% to rule out cardiac syncope was achieved with a high-sensitivity cardiac troponin T less than 5 ng/L (LR, 0.15 [95% CI, 0.08-0.31]) or a high-sensitivity cardiac troponin I less than 2.2 ng/L (LR, 0.18 [95% CI, 0.10-0.35]).²⁷ An N-terminal pro-B-type natriuretic peptide (NT-proBNP) level greater than 1966 pg/mL (LR, 5.8 [95% CI, 4.2-8.1]) was required to achieve a predefined specificity of 95% for ruling in cardiac syncope.²⁷ An elevated NT-proBNP (thresholds of >156 pg/mL¹⁹; \geq 164 pg/mL²⁰; and \geq 210.5 pg/mL²⁶) was associated with a higher likelihood of cardiac syncope, but with wide variations between studies (range of sensitivity, 90%-94%; range of specificity, 49%-98%; range of LR, 1.8-47). A predefined sensitivity of 95% to rule out cardiac syncope was achieved with an NT-proBNP less than 69 pg/L (LR, 0.16 [95% CI, 0.09-0.28]).²⁶ A normal NT-pro-BNP (thresholds of \leq 156 pg/mL¹⁹; <164 pg/mL²⁰; and <210.5 pg/mL²⁷) was associated with a lower likelihood of cardiac

Table 5. Clinical Prediction Rule for Distinguishing Seizure vs Syncope^{a,b}

| Symptom | Points | |
|--|--------|--|
| Waking with cut tongue | 2 | |
| Abnormal behavior noted ^c | 1 | |
| Loss of consciousness with emotional stress | 1 | |
| Postictal confusion | 1 | |
| Head turning to one side during loss of consciousness | 1 | |
| Prodromal deja vu or jamais vu | 1 | |
| Any presyncope | -2 | |
| Loss of consciousness with prolonged standing or sitting | -2 | |
| Diaphoresis before a spell | -2 | |
| ^a Adapted from Sheldon et al. ²⁸ | | |

^b A score \geq 1 suggests seizure and a score <1 suggests syncope.

^c Witnessed amnesia, unresponsiveness, unusual posturing, and/or limb jerking

syncope (range of LR, 0.06-0.21). About 36% of patients had a use ful NT-proBNP result that was either above the predefined thresh old for "ruling in" or below the predefined threshold for "ruling out" cardiac syncope (Table 3; eTable 10 in the Supplement).²⁷

Differentiating Syncope From Seizure

One level $3 \operatorname{study}^{28}$ (prevalence of definite seizure, 15%; n = 671 pa tients) reported the diagnostic accuracy of symptoms and signs for differentiating seizure from syncope (Table 4). The most usefu symptoms (reported by the patient or a witness) for identifying pa tients with seizures were head turning during the event (sensitivity for seizure, 43% [95% CI, 33%-53%]; specificity for seizure, 97% [95% CI, 95%-98%]; LR for seizure, 14 [95% CI, 8.2-23]), unusua posturing during the event (sensitivity for seizure, 35% [95% CI 26%-45%]; specificity for seizure, 97% [95% CI, 96%-99%]; LR for seizure, 13 [95% CI, 7.6-24]), urinary incontinence (sensitivity for sei zure, 24% [95% CI, 15%-32%]; specificity for seizure, 96% [95% CI, 95%-98%]; LR for seizure, 6.7 [95% CI, 3.8-12]), and the absence of presyncope (sensitivity for seizure, 77% [95% CI, 68%-85%]; specificity for seizure, 86% [95% CI, 83%-89%]; LR for seizure, 5.6 [95% CI, 4.4-7]). The most useful findings evaluated by the physician for identifying patients with seizures were the presence of a cur tongue (sensitivity for seizure, 45% [95% CI, 35%-55%]; specific ity for seizure, 97% [95% CI, 96%-99%]; LR for seizure, 17 [95% CI 9.9-29]) and the patient having no recall of unusual behaviors be fore the loss of consciousness (sensitivity for seizure, 53% [95% CI 43%-63%]; specificity for seizure, 87% [95% CI, 84%-90%]; LR for seizure, 4.0 [95% CI, 3.0-5.3]).

The most useful symptoms (reported by the patient or a witness) for identifying patients with syncope were loss of consciousness with prolonged sitting or standing (sensitivity for syncope, 40% [95% CI, 36%-44%]; specificity for syncope, 98% [95% CI, 95%-100%]; LR for syncope, 20 [95% CI, 5.3-100]), dyspnea before loss of consciousness (sensitivity for syncope, 24% [95% CI, 20%-27%]; specificity for syncope, 98% [95% CI, 95%-100%]; LR for syncope, 13 [95% CI, 3.0-50]), and palpitations before loss of consciousness (sensitivity for syncope, 34% [95% CI, 30%-38%]; specificity for syncope, 96% [95% CI, 92%-100%]; LR for syncope, 8.3 [95% CI, 3.2-25]). The presence of coronary heart disease was associated with a higher likelihood of cardiac syncope (sensitivity for syncope,

pe

| | The Rational Clinical Examination Clinical Review & Education |
|---|---|
| igure 2. A | Approach to Determining Whether a Patient Has Cardiac Syncop |
| 1 Pres | ence of features that suggest cardiac syncope |
| Evalua Vasova Onset Known hypert Chest of Cyanos Abnorr Featur Palpita Patien | tion of Guidelines in Syncope Study (EGSYS) score of 3 or more ^a gal score (VVS) of less than -2 ^b at age >35 years structural heart disease, atrial fibrillation/flutter, ension, or heart failure liscomfort and dyspnea is witnessed during unconsciousness mal electrocardiogram ^c es derived from recent guidelines tions t is male |
| • Family • Known | t has had 2 or fewer syncope episodes history of sudden cardiac death, syncope, or drowning congenital heart disease nal cardiac examination |
| No | Yes Assess for orthostatic hypotension and manage as possible cardiac syncope |
| | |
| 2 Pres | ence of features that suggest reflex syncope |
| • EGSYS | score less than 3 |
| • VVS sc | ore of -2 or more |
| Featu | es derived from recent guidelines |
| | otation or neck pressure prior to event |
| - | or sneeze prior to event |
| Norma | l electrocardiogram and cardiac examination |
| No | Yes Assess for orthostatic hypotension, manage as reflex syncope, and consider carotid sinus hypersensitivity |
| | |
| 3 Pres | ence of features that suggest seizure |
| Head t Unusu Urinar Cut to | ariable seizure score of 1 or more urning during event al posturing prior to event y incontinence ngue t unable to recall behaviors prior to event |
| No | Yes Assess for orthostatic hypotension and manage as possible seizure |
| ↓ | |
| | or orthostatic hypotension, rarer causes of syncope, and ng syndromes and refer for consultation with syncope specialist |
| | ach integrates the main findings of this review with the Idations of the European Society of Cardiology and American College |

recommendations of the European Society of Cardiology and American College of Cardiology/American Heart Association guidelines.^{2,29} The approach outlined has not been evaluated or validated in rigorous studies.

^a See Table 2 for an explanation of EGSYS.

^b See Table 3 for an explanation of VVS.

^c An abnormal electrocardiogram is defined in Table 2 and the Supplement.

25% [95% CI, 22%-29%]; specificity for syncope, 98% [95% CI, 95%-100%]; LR for syncope, 13 [95% CI, 3.2-50]) (Table 5).

Combinations of Findings for Seizures vs Syncope

In the same level 3 study,²⁸ the authors developed and tested a clinical prediction rule in a population of patients referred to a specialty clinic; 102 patients (15%) had seizures and 437 patients (65%) had

syncope with an established cause. The remaining 132 patients (20%) with syncope of uncertain cause were not included in the clinical prediction rule development and testing. The patients with seizures were limited to patients with electroencephalographic evidence that supported the diagnosis of seizures. In this study, some patients with seizures and normal interictal electroencephalograms would have been misclassified as having syncope, which may lead to an underestimate of accuracy of the clinical prediction rule, especially the positive likelihood ratio for ruling in seizure. The authors used logistic regression to identify 9 independently useful findings for detecting patients with seizures, and developed a simplified scoring system (range, -6 to 7; a lower score indicates a higher likelihood of cardiac syncope) (Table 5). With a score of at least 1, the model was 94% sensitive and 94% specific (LR for score \geq 1 for seizures, 16; LR for score <1 for syncope, 16; CIs cannot be derived from modeled data). The study population in which the model was developed showed a 15% prevalence of seizure, meaning that a score of at least 1 had a positive predictive value of 74% for seizure; with a 65% prevalence of established syncope, a score less than 1 had a positive predictive value of 97% for syncope.

Discussion

This review of 11 studies involving patients with suspected cardiac syncope suggests that the clinical examination can accurately identify patients with cardiac syncope. Multivariable clinical prediction rules are an attractive option because no single variable will accurately diagnose syncope (or seizure). Two level 3 studies involving a total of 456 patients evaluated the multivariable EGSYS score and showed some promise for excluding the diagnosis of cardiac syncope. Misclassification bias and other methodologic limitations could bias toward overly optimistic negative likelihood ratios, so clinicians should not use these clinical predictions alone to rule out cardiac syncope. The vasovagal score (Calgary score) showed promise in its initial study,¹⁷ but was not validated in a subsequent independent level 3 study.²⁶ Some classically taught findings lack accuracy (despite the methodologic limitations that would inflate accuracy), such as palpitations, diaphoresis, absence of prodromes, blurred vision or pallor prior to syncope, and injury after syncope.

The main findings of this review are consistent with existing European Society of Cardiology and American College of Cardiology/American Heart Association guidelines.^{2,29} Figure 2

integrates the main findings of this review with the recommendations of these 2 guidelines, leaving out biomarkers until the data are replicated and validated. Both guidelines indicate that cardiac markers, such as NT-proBNP and troponin, should not be routinely used but may be useful in select patients. Clinicians may be asked to evaluate patients after syncope in the emergency department, where biomarkers are obtained as part of patient assessment. These markers can have thresholds set so that they accurately identify patients with and without cardiac syncope, although about 65% of patients will have nondiagnostic intermediate values.²⁷ Application of the sensitivity and specificity of biomarkers for cardiac syncope requires an understanding of the assay used by each laboratory and prospectively collected data from additional populations of patients with syncope. However, the approach outlined in Figure 2 has not been evaluated or validated in rigorous studies.

This review has several limitations. Misclassification bias may have increased the estimates of sensitivity and specificity in some of the studies. Patients with unexplained syncope were excluded from some of the studies, which may have increased the sensitivity and specificity estimates. Most of the studies used structured questionnaires, trained researchers, or expert clinicians for the clinical examination, so diagnostic accuracy by less-trained clinicians is not known. About 13% of patients in the studies reviewed had a final diagnosis of unexplained syncope, highlighting the clinical challenge of establishing a final diagnosis of transient loss of consciousness when ECG findings and other critical data are not always available.

Scenario Resolution

The patient's clinical assessment revealed no features that raised the likelihood of cardiac syncope and many features that suggested that reflex syncope was more likely. In addition, her EGSYS score was -1 (range of LR, 0.12-0.17) and her vasovagal score was -1 (range of LR, 0.10-0.84), both of which made cardiac syncope less likely. The patient's multivariable score for seizure was -4, making syncope more likely (LR for score <1 for syncope, 16). There was no evidence of orthostatic hypotension, so reflex syncope was the most likely diagnosis. The physician advised the patient that if she had future similar events with warning symptoms, she should immediately lie down, elevate her legs in an effort to avoid loss of consciousness, and seek medical attention.

ARTICLE INFORMATION

Accepted for Publication: May 24, 2019.

Author Affiliations: Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (Albassam, Redelmeier, Shadowitz, Etchells); Division of Cardiology, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia (Albassam); Department of Neurology, Duke University Medical Center, Durham, North Carolina (Husain); Neuroscience Medicine, Duke Clinical Research Institute, Durham, North Carolina (Husain); Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, North Carolina (Husain); Division of General Internal Medicine, Duke Veterans Affairs Medical Center, Durham, North Carolina (Simel); Duke University, Durham, North Carolina (Simel).

Author Contributions: Dr Etchells had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Concept and design:* AlBassam, Redelmeier, Husain, Simel, Etchells. *Acquisition, analysis, or interpretation of data:* AlBassam, Redelmeier, Shadowitz, Simel, Etchells. *Drafting of the manuscript:* AlBassam, Simel, Etchells. *Critical revision of the manuscript for important intellectual content:* AlBassam, Redelmeier, Shadowitz, Husain, Simel, Etchells. *Statistical analysis:* AlBassam, Redelmeier, Shadowitz, Simel, Etchells. Administrative, technical, or material support: Redelmeier, Shadowitz, Husain, Etchells. Supervision: Shadowitz, Simel, Etchells.

Conflict of Interest Disclosures: Dr Simel reported receiving honoraria for contributions to JAMAEvidence.com and was supported by the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (CIN 13-410) at the Durham VA Health Care System. Dr Husain reported research and consultation relationships with UCB Pharmaceuticals, Jazz Pharmaceuticals, Biogen Idec, Sage Therapeutics, Eisei Pharmaceuticals, Marinus Pharmaceuticals, Neurelis Pharmaceuticals, the American Clinical Neurophysiology Society, and the American Academy of Neurology; holding an editorship with

2456 JAMA June 25, 2019 Volume 321, Number 24

Wolters Kluwer; and receiving royalties from Springer Publishers, Demos Medical Publishing, and Wolters Kluwer. No other disclosures were reported.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. Dr Simel is a section editor for the Rational Clinical Examination Series. He did not participate in the review or editorial decisions to publish the manuscript.

Additional Contributions: We thank the following individuals for validating that the reference standard classification was independent of the results of the clinical examination and multivariable prediction rules where applicable: Saeed Safari, MD (Shahid Beheshti University of Medical Sciences, Tehran, Iran), for "Validation of EGSYS Score in Prediction of Cardiogenic Syncope"; Robert Sheldon, MD, PhD (University of Calgary, Alberta, Canada), for "Historical Criteria That Distinguish Syncope From Seizures" and "Diagnostic Criteria for Vasovagal Syncope Based on a Quantitative History"; Pasquale Abete, MD, PhD (Università di Napoli Federico II, Napoli, Italy), for "Role of Early Symptoms in Assessment of Syncope in Elderly People: Results from the Italian Group for the Study of Syncope in Elderly People"; and Michael Christ, MD (Luzerner Kantonsspital, Luzern, Switzerland), for "Diagnostic and Prognostic Value of High Sensitivity Cardiac Troponin T in Patents with Syncope." We also thank Sunil Rao, MD (Division of Cardiology, Durham Veterans Affairs Medical Center and Duke University, Durham, NC), and Anthony Viera, MD (Department of Community and Family Medicine. Duke University. Durham. NC) for their comments on earlier versions of the manuscript.

REFERENCES

1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522-530. doi:10.1111/epi.13670

2. Brignole M, Moya A, de Lange FJ, et al; ESC Scientific Document Group. ESC Guidelines for the Diagnosis and Management of Syncope. *Eur Heart J.* 2018;39(21):1883-1948. doi:10.1093/eurheartj/ ehy037

3. Solbiati M, Bozzano V, Barbic F, et al. Outcomes in syncope research: a systematic review and critical appraisal. *Intern Emerg Med*. 2018;13(4): 593-601. doi:10.1007/s11739-018-1788-z

4. Sheldon R. How to differentiate syncope from seizure. *Cardiol Clin*. 2015;33(3):377-385. doi:10. 1016/j.ccl.2015.04.006

5. Passman R, Horvath G, Thomas J, et al. Clinical spectrum and prevalence of neurologic events provoked by tilt table testing. *Arch Intern Med*.

2003;163(16):1945-1948. doi:10.1001/archinte.163. 16.1945

6. Lempert T, Bauer M, Schmidt D. Syncope: a videometric analysis of 56 episodes of transient cerebral hypoxia. *Ann Neurol*. 1994;36(2):233-237. doi:10.1002/ana.410360217

7. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. *N Engl J Med*. 2002;347(12):878-885. doi:10.1056/NEJMoa012407

8. Colman N, Nahm K, Ganzeboom KS, et al. Epidemiology of reflex syncope. *Clin Auton Res.* 2004;14(suppl 1):9-17. doi:10.1007/s10286-004-1003-3

9. Institute of Medicine. *Epilepsy Across the Spectrum: Promoting Health and Understanding.* Washington, DC: National Academies Press; 2012:111-115.

10. Lüscher TF. Optimal management of syncope: the new ESC Guidelines and novel insights into its underlying causes. *Eur Heart J.* 2018;39(21):1865-1869. doi:10.1093/eurheartj/ehy309

11. Begg CB. Biases in the assessment of diagnostic tests. *Stat Med.* 1987;6(4):411-423. doi:10.1002/sim. 4780060402

12. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.* 2011;155(8):529-536. doi:10.7326/ 0003-4819-155-8-201110180-00009

13. Simel DL. A primer on the precision and accuracy of the clinical examination. In: Simel DL, Rennie D, eds. *The Rational Clinical Examination*. New York, NY: McGraw-Hill; 2009.

14. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? interpreting zero numerators. *JAMA*. 1983;249(13):1743-1745. doi:10. 1001/jama.1983.03330370053031

15. Simel DL, Bossuyt PM. Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. *J Clin Epidemiol.* 2009;62(12):1292-1300. doi:10.1016/j.jclinepi.2009. 02.007

 Menke, J. Bivariate random-effects meta-analysis of sensitivity and specificity with SAS PROC GLIMMIX. *Methods Inf Med*. 2010;49(1):54-62. doi:10.3414/ME09-01-0001

17. Sheldon R, Rose S, Connolly S, Ritchie D, Koshman M-L, Frenneaux M; Syncope Symptom Study Investigators. Diagnostic criteria for vasovagal syncope based on a quantitative history. *Eur Heart J*. 2006;27(3):344-350. doi:10.1093/ eurheartj/ehi584

18. Pfister R, Hagemeister J, Esser S, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP for diagnostic and prognostic evaluation in patients hospitalized for syncope. *Int J Cardiol*. 2012;155(2): 268-272. doi:10.1016/j.ijcard.2010.10.013

19. Pfister R, Diedrichs H, Larbig R, Erdmann E, Schneider CA. NT-pro-BNP for differential diagnosis in patients with syncope. *Int J Cardiol*. 2009;133(1): 51-54. doi:10.1016/j.ijcard.2007.11.082

20. Kariman H, Harati S, Safari S, Baratloo A, and Pishgahi M. Validation of EGSYS score in prediction of cardiogenic syncope. *Emerg Med Int.* 2015; (2015):1-5.

21. Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. *Heart*. 2008;94(12):1620-1626. doi: 10.1136/hrt.2008.143123

22. Del Rosso A, Alboni P, Brignole M, Menozzi C, Raviele A. Relation of clinical presentation of syncope to the age of patients. *Am J Cardiol*. 2005; 96(10):1431-1435. doi:10.1016/j.amjcard.2005.07.047

23. Galizia G, Abete P, Mussi C, et al. Role of early symptoms in assessment of syncope in elderly people: results from the Italian Group for the Study of Syncope in the Elderly. *J Am Geriatr Soc.* 2009; 57:18-23. doi:10.1111/j.1532-5415.2008.02070.x

24. Christ M, Geier F, Popp S, et al. Diagnostic and prognostic value of high-sensitivity cardiac troponin T in patients with syncope. *Am J Med*. 2015;128(2): 161-170.e1. doi:10.1016/j.amjmed.2014.09.021

25. Romme JJCM, van Dijk N, Boer KR, Bossuyt PMM, Wieling W, Reitsma JB. Diagnosing vasovagal syncope based on quantitative history-taking: validation of the Calgary Syncope Symptom Score. *Eur Heart J.* 2009;30(23):2888-2896. doi:10.1093/ eurheartj/ehp314

26. Stryjewski PJ, Nessler B, Kuczaj A, et al. The role of NT-proBNP in the diagnostics and differentiation of cardiac and reflex syncope in adults: relative importance to clinical presentation and medical examinations. *J Interv Card Electrophysiol*. 2014;41(1):1-8. doi:10.1007/s10840-014-9923-x

27. du Fay de Lavallaz J, Badertscher P, Nestelberger T, Zimmermann T et al. B-Type natriuretic peptides and cardiac troponins for diagnosis and risk-stratification of syncope. *Circulation* [published online February 25, 2019]. doi:10.1161/CIRCULATIONAHA.118.038358

28. Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. *J Am Coll Cardiol*. 2002;40(1):142-148. doi:10.1016/ S0735-1097(02)01940-X

29. Shen W-K, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2017;136(5):e60-e122. doi:10.1161/CIR. 000000000000499